Drugmaker Merck’s 2Q profit drops on acquisition charges, generic competition cutting revenue

WHITEHOUSE STATION, N.J. – Drugmaker Merck & Co. says its second-quarter profit fell by half because of generic competition cutting into sales and acquisition and other charges.

The maker of blockbuster diabetes pill Januvia and Gardasil, a vaccine against sexually transmitted cancers, says second-quarter net income was $906 million, or 30 cents per share, down from $1.79 billion, or 58 cents per share, a year earlier.

Excluding one-time items, the world’s third-biggest drugmaker says adjusted net income was $2.53 billion, or 84 cents per share. Analysts surveyed by FactSet expected 82 cents.

Merck, based in Whitehouse Station, N.J., says revenue totalled $11.01 billion, down 11 per cent. Analysts expected slightly higher sales of $11.24 billion.

The company backed its previous 2013 profit forecast for earnings per share of $1.84 to $2.05, excluding one-time items.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.